Elevated systemic levels of TGF-β have been reported in breast cancer, lung cancer, pancreatic cancer, glioblastoma multiforme, colorectal carcinoma, HCC, renal cell carcinoma, and gastric carcinoma (72). This evidence concerns the gene TGFB1 and lung cancer.